Cancer biopharma Meditech Research (ASX:MTR) has been offered a AUD$2.98 million AusIndustry Commercial Ready Grant over the next three years towards the development and commercialisation of its lead anti-cancer product HyCAMP, which is in Phase II clinical testing. [ + ]

Paul Hopper, who until earlier this year was at the helm of Australian company AustCancer (now Avantogen) has been named the CEO of New York-based clinical stage drug developer Evolve Oncology. [ + ]

Melbourne-based neurodiagnostic specialist CogState (ASX:CGS) has reported revenues of AUD$1.5 million for the financial year ending June 30 2005, nearly three times more than the previous corresponding period, largely through sales to major pharmaceutical companies and research institutions. [ + ]

The latest edition of PricewaterhouseCoopers' quarterly BioForum report is published today, and shows a second consecutive decline in Australian life science stocks in Q4 of the 2004-05 financial year. [ + ]

Antimicrobial specialist Chemeq (ASX:CMQ) posted a $60.7 million loss for 2004-04, 509 per cent greater than the $9.9 million it posted in the previous financial year. [ + ]

Researchers at the Western Australian Institute for Medical Research (WAIMR) have identified a key gene in acute myeloid leukaemia (AML) that could serve both as a prognostic marker and a target for new drugs to treat the disease. [ + ]

A breakfast meeting in Sydney this Friday will explore ways in which technology-based companies can get their hands on Commonwealth and NSW government grants. [ + ]

Mayne Pathology (ASX:MAY) has agreed to provide Sydney-based Medsaic's DotScan test for leukaemia and lymphoma in four states in Australia, with an official launch of the technology at Mayne Health Laverty Pathology in Sydney today. [ + ]

Drug developer Pharmaxis (ASX:PXS) has received approval to list its American Depositary Receipts (ADRs) on the Nasdaq National Market under the symbol PXSLY. [ + ]

Sirtex Medical (ASX:SRX) has been asked by the ASX to explain why its share price soared from $1.90 on August 15 to $2.45 on August 22. [ + ]

Melbourne-based novelty flower developer Florigene is planning the first field trial of its genetically modified roses carrying the company's proprietary 'blue gene' technology. [ + ]

Big pharma is licensing new projects earlier, and that means prospective partners need to be creative, a Pfizer licensing director has told a Melbourne meeting. [ + ]

Adelaide-based GroPep (ASX:GRO) has recorded pre-tax profit of AUD$3.1 million for the year ending 30 June 2005, an increase of more than 200 per cent over the $1 million reported last year. [ + ]

The Queensland government is offering $950,000 to local entrepreneurs in its start-up scheme, double the amount offered in previous years. [ + ]

RNAi specialist Benitec (ASX:BLT) and Wisconsin-based Promega have settled their contract dispute which began last year. [ + ]